These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 15486516)
1. Rivastigmine augmentation in the management of chronic schizophrenia with comorbid dementia: an open-label study investigating effects on cognition, behaviour and activities of daily living. Mendelsohn E; Rosenthal M; Bohiri Y; Werber E; Kotler M; Strous RD Int Clin Psychopharmacol; 2004 Nov; 19(6):319-24. PubMed ID: 15486516 [TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia. Stryjer R; Strous RD; Bar F; Werber E; Shaked G; Buhiri Y; Kotler M; Weizman A; Rabey JM Clin Neuropharmacol; 2003; 26(1):12-7. PubMed ID: 12567159 [TBL] [Abstract][Full Text] [Related]
3. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. Mowla A; Mosavinasab M; Haghshenas H; Borhani Haghighi A J Clin Psychopharmacol; 2007 Oct; 27(5):484-7. PubMed ID: 17873681 [TBL] [Abstract][Full Text] [Related]
4. Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease. Dujardin K; Devos D; Duhem S; Destée A; Marié RM; Durif F; Lacomblez L; Touchon J; Pollak P; Péré JJ J Neurol; 2006 Sep; 253(9):1154-9. PubMed ID: 16998649 [TBL] [Abstract][Full Text] [Related]
5. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. Modrego PJ; Pina MA; Fayed N; Díaz M CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455 [TBL] [Abstract][Full Text] [Related]
7. [Effect of AChE and BuChE inhibition by rivastigmin in a group of old-old elderly patients with cerebrovascular impairment (SIVD type)]. Servello A; Andreozzi P; Bechini F; De Angelis R; Pontecorvo ML; Vulcano A; Cerra E; Vigliotta MT; Artini M; Selan L; Ettorre E Minerva Med; 2014 Apr; 105(2):167-74. PubMed ID: 24727881 [TBL] [Abstract][Full Text] [Related]
8. Rivastigmine for dementia associated with Parkinson's disease. Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953 [TBL] [Abstract][Full Text] [Related]
9. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease. Wesnes K Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707 [TBL] [Abstract][Full Text] [Related]
10. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Olin JT; Aarsland D; Meng X Dement Geriatr Cogn Disord; 2010; 29(6):510-5. PubMed ID: 20523050 [TBL] [Abstract][Full Text] [Related]
11. Cholinesterase inhibitors for Parkinson's disease dementia. Maidment I; Fox C; Boustani M Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494 [TBL] [Abstract][Full Text] [Related]
12. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R; Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010 [TBL] [Abstract][Full Text] [Related]
13. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation. Sharma T; Reed C; Aasen I; Kumari V Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163 [TBL] [Abstract][Full Text] [Related]
14. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Giladi N; Shabtai H; Gurevich T; Benbunan B; Anca M; Korczyn AD Acta Neurol Scand; 2003 Nov; 108(5):368-73. PubMed ID: 14616309 [TBL] [Abstract][Full Text] [Related]
15. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting. Frankfort SV; Appels BA; De Boer A; Tulner LR; Van Campen JP; Koks CH; Beijnen JH Int J Clin Pract; 2006 Jun; 60(6):646-54. PubMed ID: 16805746 [TBL] [Abstract][Full Text] [Related]
16. Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. Ribeiz SR; Bassitt DP; Arrais JA; Avila R; Steffens DC; Bottino CM CNS Drugs; 2010 Apr; 24(4):303-17. PubMed ID: 20297855 [TBL] [Abstract][Full Text] [Related]
19. Rivastigmine in vascular dementia. Vincent S; Lane R Int Psychogeriatr; 2003; 15 Suppl 1():201-5. PubMed ID: 16191241 [TBL] [Abstract][Full Text] [Related]
20. Rivastigmine in subcortical vascular dementia: an open 22-month study. Moretti R; Torre P; Antonello RM; Cazzato G; Bava A J Neurol Sci; 2002 Nov; 203-204():141-6. PubMed ID: 12417373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]